207 related articles for article (PubMed ID: 20840169)
1. Self-reported side effects in buprenorphine and methadone patients receiving antiretroviral therapy: results from the MANIF 2000 cohort study.
Carrieri MP; Roux P; Cohen J; Ravaux I; Dellamonica P; Protopopescu C; Spire B; Rosenblum A
Addiction; 2010 Dec; 105(12):2160-8. PubMed ID: 20840169
[TBL] [Abstract][Full Text] [Related]
2. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
3. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
[TBL] [Abstract][Full Text] [Related]
4. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
5. Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone.
Rolland B; Trojak B; Nourredine M; Bachellier J; Chappuy M; Bendimerad P; Kosim M; Hjelmström P; Meroueh F; Nubukpo P; Brousse G
Drug Alcohol Depend; 2021 Mar; 220():108492. PubMed ID: 33482572
[TBL] [Abstract][Full Text] [Related]
6. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
[TBL] [Abstract][Full Text] [Related]
7. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders.
Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Mao J; Edwards RR; Samet JH
Drug Alcohol Depend; 2015 Aug; 153():286-92. PubMed ID: 26048638
[TBL] [Abstract][Full Text] [Related]
9. Perspectives of clients and providers on factors influencing opioid agonist treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study.
Kiriazova T; Go VF; Hershow RB; Hamilton EL; Sarasvita R; Bui Q; Lancaster KE; Dumchev K; Hoffman IF; Miller WC; Latkin CA
Harm Reduct J; 2020 Oct; 17(1):69. PubMed ID: 32998731
[TBL] [Abstract][Full Text] [Related]
10. The medical management of opioid dependence in HIV primary care settings.
Lum PJ; Tulsky JP
Curr HIV/AIDS Rep; 2006 Nov; 3(4):195-204. PubMed ID: 17089480
[TBL] [Abstract][Full Text] [Related]
11. Relationship between choice of opioid agonist therapy and distance from patients' residences in Taiwan, 2012-2014.
Wei LC; Chan HY
Am J Drug Alcohol Abuse; 2021 Sep; 47(5):590-598. PubMed ID: 34402338
[TBL] [Abstract][Full Text] [Related]
12. Assessing the Temporality Between Transitions onto Opioid Agonist Therapy and Engagement with Antiretroviral Therapy in a Cohort of HIV-Positive People Who Use Opioids Daily.
Mitra S; Grant C; Nolan S; Mohd Salleh NA; Milloy MJ; Richardson L
AIDS Behav; 2022 Jun; 26(6):1933-1942. PubMed ID: 34977956
[TBL] [Abstract][Full Text] [Related]
13. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.
Umbricht A; Hoover DR; Tucker MJ; Leslie JM; Chaisson RE; Preston KL
Drug Alcohol Depend; 2003 Apr; 69(3):263-72. PubMed ID: 12633912
[TBL] [Abstract][Full Text] [Related]
14. Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?
Reed LJ; Glasper A; de Wet CJ; Bearn J; Gossop M
J Clin Psychopharmacol; 2007 Apr; 27(2):188-92. PubMed ID: 17414244
[TBL] [Abstract][Full Text] [Related]
15. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
[TBL] [Abstract][Full Text] [Related]
16. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
17. Viral suppression among HIV-infected methadone-maintained patients: The role of ongoing injection drug use and adherence to antiretroviral therapy (ART).
Shrestha R; Copenhaver MM
Addict Behav; 2018 Oct; 85():88-93. PubMed ID: 29879611
[TBL] [Abstract][Full Text] [Related]
18. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History.
Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA
J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674
[TBL] [Abstract][Full Text] [Related]
20. Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Dore GJ; Altice F; Litwin AH; Dalgard O; Gane EJ; Shibolet O; Luetkemeyer A; Nahass R; Peng CY; Conway B; Grebely J; Howe AY; Gendrano IN; Chen E; Huang HC; Dutko FJ; Nickle DC; Nguyen BY; Wahl J; Barr E; Robertson MN; Platt HL;
Ann Intern Med; 2016 Nov; 165(9):625-634. PubMed ID: 27537841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]